ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) 14 November 2012 PRIMA BIOMED RELEASES INTERIM IMMUNE MONITORING DATA FROM CVAC CLINICAL TRIAL Interim immune monitoring data demonstrate positive effe

ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)

PRIMA BIOMED RELEASES INTERIM IMMUNE MONITORING DATA FROM CVAC CLINICAL TRIAL

Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima, the Company ) today released interim immune monitoring data

from its ongoing CAN-003 clinical trial of CVac to treat epithelial ovarian cancer patients in remission after first-line or second line therapy.

The interim data demonstrate the positive effects of CVac treatment on the immune system.

Company has completed intracellular cytokine staining ( ICS ) analysis of seven patients from the CAN-003 trial five patients from the CVac group and two patients from the control group, who did not receive any cancer treatment

As compared to the control group, the CVac patients demonstrated much higher T cell activity throughout the testing period.

ICS testing also indicates that the T cell response is specific to mucin 1, the antigen marker present on most ovarian cancer cells.

Ian Frazer, the chairman of Prima s scientific advisory board commented: There is clear evidence of a cellular response to mucin 1 induced by CVac treatment. We look forward to further analysis of all patients on the CAN-003 study to see

if these early trends are confirmed.

Matthew Lehman, Prima s CEO stated: We are encouraged by the interim trends we have

seen in the CAN-003 data released to date. CVac has a very favourable side effect profile, the clinical data in terms of progression free survival are trending in the right direction, and the early ICS data support our hypothesis of how the product

should work in a patient s body.

ICS is a laboratory technique used to evaluate if CVac has induced a desired

mucin 1 specific T cell response in patients treated with CVac. The ICS results help confirm the biological activity of CVac.

Prima will make a presentation of the CAN-003 interim data via a conference call and webcast on Thursday November 15th at 9:00am (Sydney local time).

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

2 9276 1224 Fax: +61 2 9276 1284

Conference call and webcast details:

Conference call dial-in numbers:

The webcast can be accessed via the following link;

Before launching the webcast,

it is recommended to click on the link and then on Test your systems configuration. A replay of the teleconference and webcast will be available through Prima s website following the live event.

Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging

its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima s lead product is CVac , an autologous dendritic cell product currently in clinical trials for ovarian

cancer patients who are in remission.

CAN-003 is an open label, randomized, multinational, controlled phase 2 study. Sixty-three ovarian cancer patients in first or second remission have been enrolled. The first seven patients were not

randomized and all received CVac. Subsequently, 29 patients were randomized to the CVac group compared to 27 patients in the observation standard of care group.

For further information please contact:

Australia Investor/Media

Mr. James Moses, Mandate Corporate

(0) 420 991 574; james@mandatecorporate.com.au

Ms. Kathy Galante, Burns McClellan Inc.

+1 (212) 213-0006; kgalante@burnsmc.com

Europe Investor/Media:

Mr. Axel M hlhaus, edicto GmbH

(0) 69 905505-52; amuehlhaus@edicto.de

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000

Phone: +61 2 9276 1224 Fax: +61 2 9276 1284